Overview
AURA market data
Price History
AURA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.76 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.42 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.73 – $9.54 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $793.3M · P/B 2.53.
Company News
Auro Biosciences shares are trading lower after the company announced it may offer securities up to an aggregate of $500 million and may sell up to $200 million shares under a sales agreement with Jefferies.Benzinga · Aug 12, 2026, 12:00 PM
Aura Biosciences May Offer Securities Up To $500M Aggregate; May Sell Up To $200M Common Stock Under Sales Agreement With JefferiesBenzinga · Aug 11, 2026, 8:56 PM
HC Wainwright & Co. Maintains Buy on Aura Biosciences, Lowers Price Target to $18Benzinga · Aug 11, 2026, 4:11 PM
Aura Biosciences Q2 EPS $(0.48) Misses $(0.38) EstimateBenzinga · Aug 11, 2026, 11:22 AM
8-K filing — Aura Biosciences, Inc. (AURA)SEC EDGAR · Aug 11, 2026, 11:05 AM
Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga · Jul 24, 2026, 12:04 PM
Why SAP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving PremarketBenzinga · Jul 24, 2026, 8:35 AM
Aura Biosciences Announces 108 Patients Enrolled In The Phase 3 Trial Evaluating Belzupacap Sarotalocan As A Frontline Treatment For Patients With Early Choroidal Melanoma; Topline Data Expected In H2 2027Benzinga · Jun 1, 2026, 12:14 PM
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Globenewswire Inc · May 19, 2026, 9:15 PM